TAPENTADOL — 100 mg / 200 mg tablets (IR & ER)

Tapentadol is a centrally‑acting synthetic analgesic with a unique dual mechanism of action. It is the first representative of a new class of analgesics known as MOR‑NRI, combining mu‑opioid receptor (MOR) agonism with norepinephrine reuptake inhibition (NRI) in a single molecule. This multimodal approach differentiates it from classical opioids like morphine and oxycodone.

Mechanism of action: Tapentadol exerts its analgesic effects through two distinct pathways. First, it acts as an agonist at the mu‑opioid receptor, although with approximately 18‑fold lower potency than morphine. Second, it inhibits the reuptake of norepinephrine in the central nervous system, enhancing descending inhibitory pain pathways. Both mechanisms contribute to analgesia in a synergistic manner, meaning that relatively moderate activity at each target produces strong analgesic effects. In persistent neuropathic pain models, the NRI component becomes predominant.

Clinical profile: Tapentadol is effective across a broad spectrum of pain types, including nociceptive, inflammatory, and neuropathic pain. In clinical studies, it demonstrates analgesic efficacy comparable to strong opioids such as oxycodone, but with improved gastrointestinal tolerability (less nausea, vomiting, constipation). This favorable side effect profile is attributed to its only partial reliance on opioid mechanisms. Tapentadol is available as an immediate‑release formulation for acute pain and an extended‑release formulation for continuous, around‑the‑clock pain management, including neuropathic pain associated with diabetic peripheral neuropathy.

Regulatory context: Tapentadol is a Schedule II controlled substance in the United States, reflecting its high potential for abuse, psychological and physical dependence, and risk of severe withdrawal. It was placed in Schedule II in 2009 following FDA approval. It is contraindicated in patients receiving monoamine oxidase inhibitors (MAOIs) due to the risk of severe cardiovascular events and serotonin syndrome. Tapentadol is not recommended for use in severe hepatic impairment and requires dose adjustment in moderate impairment.

• Significant respiratory depression (unmonitored settings, absence of resuscitative equipment).
• Acute or severe bronchial asthma, hypercapnia (unmonitored settings).
• Paralytic ileus or suspected gastrointestinal obstruction.
• Current use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI.
• Hypersensitivity to tapentadol or any excipient.

• Hepatic impairment: Mild (Child‑Pugh A) — no adjustment. Moderate (Child‑Pugh B) — reduced dose, extended dosing interval. Severe (Child‑Pugh C) — contraindicated (4.2‑fold increase in AUC).
• Renal impairment: No dose adjustment needed, but metabolite (tapentadol‑O‑glucuronide) accumulates; monitor for adverse events. Insufficient data for ESRD/hemodialysis.
• Pregnancy: Category C. Prolonged use may cause neonatal opioid withdrawal syndrome. Avoid use during pregnancy unless benefit outweighs risk.
• Breastfeeding: Tapentadol and metabolites excreted in milk. Monitor infant for increased sleepiness, breathing difficulties, limpness. Seek immediate care if these signs occur.
• Pediatric (<18 years): Safety and efficacy not established. Pediatric use information is approved but limited by marketing exclusivity.
• Geriatric (>65 years): Caution advised. Lower starting doses may be needed due to increased sensitivity to CNS effects.

• MAOIs (phenelzine, tranylcypromine, selegiline, isocarboxazid, linezolid, methylene blue): Contraindicated — risk of severe cardiovascular events and serotonin syndrome. Allow 14‑day washout.
• CNS depressants (benzodiazepines, gabapentinoids, other opioids, alcohol, sedatives, hypnotics, antipsychotics, TCAs): Additive respiratory depression, profound sedation, coma, death. Avoid or reserve for patients with inadequate alternatives and monitor closely.
• Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, St John‘s wort): Serotonin syndrome risk. Monitor for symptoms (agitation, hallucinations, tachycardia, hyperthermia, hyperreflexia).
• Alcohol: Avoid completely. Potentiates CNS depression, increases risk of overdose, and may cause additive impairment of judgment and motor skills.
• Mixed opioid agonist/antagonists (buprenorphine, nalbuphine, pentazocine): May reduce analgesic efficacy and precipitate withdrawal.
• Muscle relaxants: Enhanced neuromuscular blockade and respiratory depression.
• CYP enzyme interactions: Minimal. Tapentadol primarily metabolized by Phase 2 glucuronidation, not CYP450; drug‑drug interactions via CYP are unlikely.

• Symptoms: Respiratory depression (rate and/or tidal volume decreased, Cheyne‑Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, hypotension, pulmonary edema, death.
• Management: Establish patent airway, provide assisted or controlled ventilation. Administer naloxone if available (may need repeated doses due to tapentadol‘s longer duration). Consider activated charcoal if ingestion recent. Monitor for at least 24 hours.